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• Synthesis of a range of 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles (PT)   
 
• In vitro cytotoxicity of PTs on human breast cancer cell lines was evaluated 
 
• The effects of two promising compounds on cancer biology was studied 
 
• The reported results indicate that the studied compounds may induce DNA 
damage 
 
• Introduce the potential of PTs for the therapy of triple-negative breast cancer 
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Abstract − Further studies on 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles as anticancer agents against 
breast cancer are reported, allowing to demonstrate the potential of these compounds for the therapy of the triple-negative 
breast cancer, the most challenging tumors in clinical practice. These compounds were assayed for their in vitro 
cytotoxicity on several human breast cancer cell lines (MCF7, HCC1954 and HCC1806 cell lines). Particularly 
interesting were the results obtained for 4-hydroxyphenyl substituted derivative, which proved to be the most promising 
compound regarding HCC1806 cell line, a triple-negative breast cancer. The effects of the two most active compounds 
on cell survival, viability, cell cycle, DNA damage and expression of proteins related to cell death pathways were 
studied. The reported results consolidate the potential of 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles for the 
therapy of breast cancer, particularly the triple-negative. 
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Keywords: 6,7-Bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazole / Antitumor activity / Breast cancer / Triple-negative 
breast cancer 
 
 
1. Introduction  
Breast cancer is the most common cause of tumor malignancy in woman [1]. The breast cancer 
susceptibility genes (BRCA) 1 and 2 are the most associated with breast cancer. BRCA1 gene is 
important in the normal breast development promoting the expression of estrogen receptors (ER) and 
BRCA2 gene is responsible for the mechanism of DNA repair by homologous recombination (HR). 
Mutations in BRCA genes result in a more aggressive and metastatic phenotype, usually referred as 
BRCAness phenotypes. However, these are the types of cancer more susceptible to chemotherapy 
due to their compromised DNA repair mechanism [2]. Even triple-negative breast cancers (TN - 
which have negative histochemical confirmation for ER, progesterone receptor, RP, and human 
epidermal growth factor receptor 2, HER2), without mutations in BRCA genes have also been 
described as having a BRCAness phenotype and are as sensitive to chemotherapy [3]. 
The triple-negative breast cancer is an extremely aggressive form of breast cancer that occurs most 
often in young women. It is difficult to treat successfully because there are no targeted therapies 
available as it lacks the receptors usually used for clinical stratification. Triple-negative breast 
cancers tend to present higher grades, larger tumours, higher metastasis incidence and a shorter time 
of recurrence compared with other breast cancers types. The lack of adequate therapeutic response 
for TN breast cancers makes the search for new anti-cancer agents extremely relevant. Thus, we 
were particularly interested in finding compounds with anti-triple-negative breast cancer properties.  
In recent years we have studied chiral hydroxymethyl-1H,3H-pyrrolo[1,2-c]thiazoles as promising 
antiproliferating agents against breast cancer [4,5], leading to the synthesis of chiral 6,7-
bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazole as the most promising scaffold for the design of 
new potent anticancer compounds against breast cancer. 
Structure-activity relationship (SAR) studies of several 1H,3H-pyrrolo[1,2-c]thiazole derivatives 
(e.g. 1-6) against breast adenocarcinoma MCF7 cell line allowed the establishment of structural 
features for antitumor activity, Figure 1 [4,5].  It was demonstrated that only 1H,3H-pyrrolo[1,2-
c]thiazoles bearing hydroxymethyl substituents show in vitro anticancer activity. On the other hand, 
the position of the hydroxymethyl substituent is crucial. In fact, derivative 1 with this group at C-6 is 
active whereas the C-7 substituted derivative 2 showed low activity. Nevertheless, the presence of 
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two hydroxymethyl groups leads to a slight improvement in activity against MCF7 breast cancer cell 
lines as illustrated by 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazole 3 with IC50 value of 1.1 
µM. Furthermore, the combined presence of a phenyl group at C-3 and a methyl group at C-5 in the 
1H,3H-pyrrolo[1,2-c]thiazole ring system is essential to ensure high cytotoxicity. Interestingly, 
pyrrolo[1,2-c]thiazole 6 showed even better performance against breast cancer cell lines than the 
corresponding enantiomer 3. 
In an effort to produce new structures with better anticancer activity and that may give additional 
knowledge on SAR, based on structure 3, we synthesized and evaluated the effect of replacing the 
phenyl substituent at C-3 by a 4-methoxyphenyl group 9a and by the more hydrophilic 4-
hydroxyphenyl group 9b. The 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazole 12, derived 
from penicillamine, has also been studied in order to determine whether the presence of two methyl 
groups at C-1 would lead to enhance cytotoxic activity. The new compounds were assayed for their 
in vitro cytotoxicity on several human breast cancer cell lines, including TN breast cancer cell lines. 
So far our studies were limited to cytotoxicity of the compounds synthesized. However, to 
understand the mechanism of action and the effects on cancer biology further studies were needed. 
Therefore, we evaluated the effects of two promising compounds on cell survival, viability, cell 
cycle, DNA damage and expression of proteins related to cell death pathways. 
 
2. Results and Discussion 
 
2.1 Chemistry  
 
Chiral 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles 9a and 9b were prepared as outlined 
in Scheme 1, following a known general synthetic procedure [4].  2-Phenylthiazolidine-4-carboxylic 
acids 7 were obtained as a mixture of 2R,4R- and 2S,4R-diastereoisomers from the reaction of L-
cysteine with the appropriate aldehyde. Thiazolidines 7 were heated in a solution of acetic anhydride 
in the presence of dimethyl acetylenedicarboxylate. Under these reaction conditions the N-acylation 
of thiazolidines occurs in situ, followed by 1,3-dipolar cycloaddition via a bicyclic münchnone 
intermediate. The chirality at C-4 of the starting thiazolidine is lost and the chirality at C-2 (C-3 in 
the product) is retained giving 1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylates 8 as single 
enantiomers with R configuration at C-3. The cycloaddition of the münchnone generated from 
thiazolidine 7b gave 3-(4-acethoxyphenyl)-1H,3H-pyrrolo[1,2-c]thiazole 8b, resulting from the 
acetylation of the initially formed dimethyl (3R)-3-(4-hydroxyphenyl)-5-methyl-1H,3H-pyrrolo[1,2-
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c]thiazole-6,7-dicarboxylate. Reduction of 1H,3H-pyrrolo[1,2-c]thiazoles 8 with lithium aluminium 
hydride afforded the corresponding 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles 9 in 
moderate yield. In the case of acetylated derivative 8b simultaneous deprotection of the hydroxyl 
group has occurred giving compound 9b. 
A similar synthetic strategy was applied in the synthesis of (3S)-3-phenyl-1,1,5-trimethyl-6,7-
bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazole  (12) (Scheme 2). 5,5-Dimethyl-2-
phenylthiazolidine-4-carboxylic acid (10) was prepared as a mixture of 2R,4S- and 2S,4S-
diastereoisomers from the reaction of D-penicillamine with benzaldehyde. The 1,3-dipolar 
cycloaddition of the münchnone, generated from thiazolidine 10, gave 1H,3H-pyrrolo[1,2-c]thiazole-
6,7-dicarboxylate 11 as a single enantiomer with S configuration. 6,7-Bis(hydroxymethyl)-1H,3H-
pyrrolo[1,2-c]thiazole 12 was obtained in 51% yield by the reduction of compound 11 with lithium 
aluminium hydride. 
 
2.2 Biological evaluation 
 
2.2.1 In vitro antiproliferative activities and SAR 
The new compounds were evaluated for their in vitro anti-proliferative activity against human 
breast cancer representative of HER2+ (HCC1954), RH+ (MCF7) and TN (HCC1806) tumors (Table 
1). In the HCC1954 cell line none of the compounds affect cell proliferation at 24 h of incubation. 
However, when cells were incubated for 48 h with the studied compounds a significant decrease in 
IC50 values was observed (3, 9a and 9b p<0.001; 6 p=o.019; 12 p=0.017). 3 is the most promising 
anti-proliferative compound against HCC1954 cells and the less promising is 9a. In the MCF7 cell 
line, 3 and 6 are the most promising compounds concerning anti-proliferative activity with IC50 
values of 0.6 µM and 0.3 µM, respectively, for 96 h incubation time. On the other hand, 12 showed 
no anti-proliferative activity against MCF7 cell line, in the concentrations tested, up to 100 µM. 
Despite the fact that 9a and 9b showed moderate anti-proliferative activity in MCF7 cell line, the 
decreasing IC50 value over time has statistical significance (p<0.05). In the HCC1806 cell line, 9b is 
the most promising compound with significant decrease of IC50 value over time (p<0.05), with IC50 
value of 5.4 µM for 96 h incubation time. All the other compounds showed a significant decrease in 
the IC50 value going from 24 h to 48 h incubation time (p<0.001), being 3 and 6 the less active 
compounds in this cell line. 
The design of new compounds has been guided considering 3 as the lead compound [5] and the 
structural modifications were thought not only to obtain derivatives with higher anti-proliferation 
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activity, but also to gather data regarding SAR. We showed that the presence of the phenyl group at 
C-3 seemed to be important to the activity of the compounds [5]. However, in previous studies, the 
possibility of replacing the phenyl group by other aryl groups such as 4-methoxyphenyl and 4-
hydroxyphenyl substituents was not explored. In this context, we synthesized 3-(4-methoxyphenyl)-
1H,3H-pyrrolo[1,2-c]thiazole 9a and 3-(4-hydroxyphenyl)-1H,3H-pyrrolo[1,2-c]thiazole 9b. 
Regarding MCF7 cell line the new derivatives show lower activity than the lead compound 3. 
However, these compounds presented better anti-cancer activity than 1H,3H-pyrrolo[1,2-c]thiazole 
3, against TN cell line, HCC1806, which is more challenging to treat and lack a targeted therapy. 
Particularly interesting were the results obtained for 4-hydroxyphenyl substituted derivative 9b, 
which prove to be the most promising compound regarding HCC1806 cell line, a TN-breast cancer. 
So far, all the compounds studied in our group were unsubstituted at C-1. Thus, 1,1-dimethyl-
1H,3H-pyrrolo[1,2-c]thiazole 12 was synthesized and its biological evaluation as anticancer activity 
against HCC1806, HCC1954 and MCF7 breast cancer human cell lines was carried out (Table 1). 
However, the IC50 values obtained for 12 were rather high in comparison with other studied 
compounds. Thus, from current and previous results, we can conclude that substitution at C-1 by 
methyl groups does not improve anti-cancer activity of 1H,3H-pyrrolo[1,2-c]thiazole derivatives. 
Moreover, 12 has the S absolute configuration at C-3, which potentiates cytotoxic activity against 
MCF7 cell line, as we already discussed. These results indicate that the substitution pattern in the 
pyrrolo[1,2-c]thiazole ring system plays a more significant role in the anti-proliferative activity than 
the absolute configuration at C-3. 
 
2.2.2 Cell cultures are sensitive to treatment 
Since 1H,3H-pyrrolo[1,2-c]thiazoles 3 and 9b are promising due to their anti-proliferative activity 
against HR+ MCF7 cell line and TN HCC1806 cell lines, we tested the long-term sensitivity and 
survival of a cell culture to the treatment performing the clonogenic assay. As we can observe in 
Figure 2, all treatments reduces significantly (p<0.001) the surviving factor of both cell cultures. It is 
further noticed that HC 1806 cell line is particularly sensitive to treatment since surviving factor is 
below 2%. 
These results show that HCC1806 cell line in particular presents high sensitivity to chemotherapy 
with these compounds, proving that this cell line presents a BRCAness phenotype. It is further 
noticed that treatment with 3, which is the compound that presents the higher IC50 value, is the one 
that most affects HCC1806 survival. 
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2.2.3 Cell mass and total protein production is reduced 
The total protein content was analyzed after treatment of MCF7 and HCC1806 cell lines with 
1H,3H-pyrrolo[1,2-c]thiazoles 3 and 9b  (Figure 3). HCC1806 cell line reduces the total protein 
content to about 50% when treated with any of the compounds. In the MCF7 cell line, treatment with 
3 produces similar results to those of HCC1806 cell line, but treatment with 9b reduces total protein 
content to 15.4±9.4%. The reduction of protein content showed statistical significance in all 
conditions of treatment in both cell lines (p<0.001). SRB assay allows us to conclude that cell mass 
is significantly reduced with treatment, which indicates that cell viability is also significantly 
reduced. 
 
 
2.2.4 PT induce cell death preferentially by late apoptosis and necrosis 
In view of the high cytotoxicity exhibited against MCF7 and HCC1806 by 1H,3H-pyrrolo[1,2-
c]thiazoles 3 and 9b and SRB assay results which indicates a reduced viable cell mass, flow 
cytometry studies were performed with IC50 values of these compounds at 48 h to determine cell 
viability and the induced mechanism of cell death (necrosis or apoptosis). The graphs showed in 
Figure 4 presents the percentage and standard deviation for populations of four different cell states: 
living cells (negative for An-V and PI), apoptotic cells (negative for PI and positive for An-V), late 
apoptotic or necrotic cells (positive for An-V and PI) and necrotic cells (negative for An-V and 
positive for PI). 
For the MCF7 cell line it is observed that 3 induces a decreasing in the viable cells population 
(p=0.015) and an increasing in the late apoptotic/necrotic (p=0.048) and in the necrotic populations 
(p=0.001). 9b effects in MCF7 cell line decreased viable cells population to 21.4±4.2% (p<0.001), 
and increased apoptotic (p=0.001), late apoptotic/necrotic (p<0.001) and necrotic (p=0.006) 
populations, comparing to the control. 
In the TN cell line, HCC1806, both 3 and 9b decreases viable cells population (3: p<0.001; 9b: 
p=0.022) and increases late apoptosis/necrosis (3: p<0.001; 9b: p=0.011) and necrosis (3: p<0.001; 
9b: p=0.019). HCC1806 cell line is characterized by a 2bp insertion after the nucleotide 256 in the 
4th exon in 17p13.1 chromosome [6], which encodes p53, causing a frame shift which results in a 
shorter protein with only 122 aminoacids. Therefore HCC1806 lacks p53 expression7 due to the 
degradation of a non-functional p53 protein and, as consequence, cellular death by apoptosis is 
diminished. That is the reason why p53 loss is correlated with multidrug resistance and also with 
defective cell proliferation control, inefficient DNA repair and genetic instability and that contributes 
to the aggressive phenotype due to cumulative genetic alteration [7].  
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On the other hand, MCF7 cell line expresses the wild-type p53 [7], which could explain the 
duality of response to treatment in the clonogenic assay and viability and types of cell death. That is, 
cell viability is reduced to about 55/60% when both cell lines are treated with 3 and also late 
apoptotic/necrotic and necrotic populations are significantly increased which means that the response 
to treatment is probably p53 independent. However, when cells are treated with 9b their response is 
very distinct. MCF7 viability is significantly reduced to 21.4±4.2% and the apoptotic population is 
significantly increased, although with time cells are able to recover as observed with the clonogenic 
assay, which means that, initialy the majority of cells are affected and die but the remaining cells are 
able to recover after treatment. On the other hand HCC1806 is more resistant to cell death and 
clearly cell death through apoptosis is compromised since cell death is mainly necrotic with both 
treatments but its long-term survival is significantly reduced to 1.4±0.3%. 
 
2.2.5 p53 Expression is influenced by 1H,3H-pyrrolo[1,2-c]thiazole 3 
Although the p53 profile of the two cell lines is known, we confirmed that the HCC1806 cell line 
lacks its expression. Nevertheless we evaluated p53 expression by western blot to access this protein 
in the MCF7 cell line in response to treatment.  
As we can observe in Figure 5, p53 is increased with treatment in the MCF7 cell line, with a 
significant effect with 9b treatment (p<0.009). This result corroborates the increasing of the 
apoptotic population after 9b treatment, and the slight non significant increase of p53 expression 
compared to control, after 3 treatment, explains why cell death is not related to apoptosis. 
 
 
2.2.6 1H,3H-Pyrrolo[1,2-c]thiazole increases Bax/Bcl-2 ratio 
We also assessed the ratio of the expression of Bax, a pro-apoptotic protein, and Bcl-2, an anti-
apoptotic protein, two proteins involved in the apoptotic cell death (Figure 6). Briefly, this pathway 
is mainly activated in response to DNA damage, which can activate p53 resulting in the expression 
of Bax and repression of BCl-2 proteins. Later, Bax leads to the cytochrome c release from 
mitochondria and later caspase activation, ultimately causing cell death by apoptosis [7,8].  
Comparing to the control, the ratio Bax/Bcl-2 is increased in all treatments, however only 
treatment with 9b increase this ratio with statistical significance (MCF7: p=0.003; HCC1806: 
p<0.001). As we can observe Bax/Bcl-2 ratio in the MCF7 cell line is consistent with results of cell 
death and p53 expression, where only treatment with 9b was able to induce a significant increase in 
the apoptotic cell population. 
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Despite the fact that HCC1806 cell line does not express p53, the Bax/Bcl-2 ratio is significantly 
increased with 9b treatment. This might have to do with the default Bax activation when anti-
apoptotic proteins such as Bcl-2 are neutralized or their expression is diminished [9]. However cell 
death is mainly necrotic, which means that other mechanisms of cell death might be predominant. 
For instance, poly(ADP-ribose)polymerase-1 (PARP-1) promotes cell death by apoptosis when DNA 
damage is moderate and cell death by necrosis in the presence of extensive DNA damage, but also 
the balance between apoptosis and necrosis is dependent of the cell type [10]. With that in mind 
1H,3H-pyrrolo[1,2-c]thiazole 3 could cause severe DNA damage and activate PARP-1 causing 
necrotic cell death, and also HCC1806 cell line could be more sensitive to the activation of this 
protein since both treatments cause necrotic cell death. 
 
 
2.2.7 1H,3H-Pyrrolo[1,2-c]thiazole blocks cell-cycle progression preferentially at S phase 
The growing evidence that these compounds could induce DNA damage led to the analysis the 
progress/blockade of cell cycle of MCF7 and HCC1806 cell lines after treatment with 3 and 9b. In 
the MCF7 cell line, both 3 and 9b, as represented in Figure 7, decreased population of cells in the 
G0/G1 (3 and 9b: p<0.001) and increased cell population in the S phase (3 and 9b: p<0.001). A 
blockade in the G2/M phases is induced by compound 3 (p=0.001) but not by 9b (p>0.05). Both 
intra-S [11] and the G2/M [12] checkpoints are mostly related to stalled replication forks that can 
derived from DNA inter-strand crosslinks. When this particular type of DNA damage is detected, 
ataxia telangiectasia and Rad3 related (ATR) is activated and promotes mainly checkpoint protein 
kinase 1 (Chk1) phosphorylation [12], a protein responsible for the intra-S phase arrest in order to 
promote DNA repair [11]. Also, Chk1-P is able to activate p53 protein, upregulating p21WAF1 which 
inhibit the cyclin-dependent kinase 1-cyclin B complex (Cdk1-cyclin B) and cause cell cycle G2/M 
phase arrest [12].  
As can be observed in Figure 7, 3 induces a blockade in the G0/G1 phase in HCC1806 cell line 
(p=0.001), but has no effect in the other phases of the cell cycle, indicating a state of quiescence 
where cells stop dividing [13]. Similarly to treatment in the MCF7 cell line, 9b produced a decreased 
population of HCC1806 cells in the G0/G1 (p<0.001) and an accentuated accumulation of cells in 
the S phase (p<0.001) and in the pre-G0 phase (p=0.011). These results indicate DNA degradation 
and intra-S phase arrest with the objective to promote DNA repair [11] as previously explained. 
 
2.2.8 Comet Assay in the MCF7 and HCC1806 cell lines 
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Because of the chemical structure of the compounds it was proposed that they could be able to act 
by mono and bis-alkylation of DNA. The alkaline comet assay (pH>13) allows to detect DNA 
damage in individual eukaryotic cells, namely, single strand breaks, double strand breaks, alkaline 
labile sites, and transient repair sites [14]. As can be observed in Figure 8, cells treated with IC50 and 
with three times more this concentration do not show evidence of DNA breaks, in contrast with the 
positive controls with hydrogen peroxide. In fact, cells from treatment have the same appearance as 
the negative controls. However, we cannot exclude the possibility of intrastranded or interstranded 
crosslinking formation. Interstranded crosslinking is also a cytotoxic form of DNA damage once 
DNA strands separation is prevented and DNA replication is blocked. Concerning comet assay the 
presence of crosslinks results in less DNA migration [15].  
 
 
3. Conclusion 
 
Herein, in the continuation of our series of studies on the hydroxymethyl-1H,3H-pyrrolo[1,2-
c]thiazoles as anticancer agents against breast cancer, we introduce the potential of these compounds 
also for the triple-negative breast cancer, the most challenging tumors in clinical practice. 
The study allowed us to redraw some conclusions regarding structure-activity relationships. Thus, 
the results of the in vitro activity have demonstrated that the presence of methyl groups at C-1 in the 
1H,3H-pyrrolo[1,2-c]thiazole ring system is prejudicial for their activity, in all cell lines studied. The 
presence of a hydroxyphenyl group at C-3 seems to improve the anti-cancer activity for the TN cell 
line. These results, together with our previous ones, indicate that there is a differential anti-cancer 
activity concerning the biochemical profile of the cell lines, therefore future modifications must be 
envisioned taking this into account. 
Furthermore, it is the first time that cellular effects beyond cytotoxicity are explored adding a new 
and valuable role in the screening of our compounds, giving a first insight into their mechanism of 
action. Both cell lines are sensitive to 3 and 9b being the TN cell line HCC1806 survival the most 
affected/reduced. Viability is also decreased and cell death related proteins p53, Bax and Bcl-2 are 
significantly altered, occurring cell cycle blockage mainly in S-phase and cell death mostly by late 
apoptosis and necrosis. The reported results indicate that the studied compounds may induce DNA 
damage. 
Our studies in this family of compounds consolidate the potential of hydroxymethyl-1H,3H-
pyrrolo[1,2-c]thiazoles for the therapy of breast cancer, particularly the triple-negative, an asset to 
continue with pre-clinic studies. 
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4. Experimental Section 
 
4.1 Synthetic Procedures 
 
4.1.1 General Methods 
1H NMR (400 MHz) and 13C NMR (100 MHz) spectra were recorded on a Bruker Avance III 400 
MHz spectrometer. Chemical shifts (δ) are expressed in parts per million (ppm) related to internal 
TMS, and coupling constants (J) are in hertz. The following abbreviations are used in the assignment 
of NMR signals: s (singlet), d (doublet), m (multiplet), bs (broad singlet). IR spectra were recorded 
on a Nicolet 6700 FTIR spectrometer. HRMS spectra were obtained on a VG Autospect M 
spectrometer (TOF MS EI+ or ESI). Melting points were determined in open glass capillary with an 
Electrothermal melting point apparatus and are uncorrected. Optical rotations were measured on an 
Optical Activity AA-5 electrical polarimeter. Flash column chromatography was performed with 
silica gel 60 as the stationary phase. TLC analyses were carried out on Merck Silica gel 60 F254 
plates. 1H,3H-Pyrrolo[1,2-c]thiazoles 3 [4] and 6 [5] were prepared as described in the literature. 
 
4.1.2 General procedure for the synthesis of 1,3-thiazolidine-4-carboxylic acids 7 
A solution of the appropriate aldehyde (40.0 mmol) in ethanol (30 mL) was added to a solution of 
L-cysteine (5.0 g, 40.0 mmol) in water (40 mL). After stirring overnight at room temperature the 
product was filtered and washed with diethyl ether. 
 
4.1.2.1. 2-(4-Methoxyphenyl)-1,3-thiazolidine-4-carboxylic acid (7a). Yield: 89% (8.5 g), white 
solid, mp 166-168 ºC (lit. [16] 156-158 ºC). The 1H NMR spectrum obtained at 40 ºC showed the 
presence of the two diastereoisomers (2R,4R) and (2S,4R) (ratio 48:52); 1H NMR (400 MHz, 
(CD3)2SO): δ = 3.05-3.10 and 3.14-3.18 (1H, 2 x m, ABX), 3.29-3.32 and 3.35-3.39 (1H, 2 x m, 
ABX), 3.75 and 3.76 (3H, 2 x s), 3.85-3.89 and 4.23-4.26 (1H, 2 x m, ABX), 5.46 and 5.62 (1H, 2 x 
s, CHAr), 6.89 and 6.93 (2H, 2 x d, J = 8.6 Hz, ArH), 7.37 and 7.44 (2H, 2 x d, J = 8.5 Hz, ArH). 
 
4.1.2.2. 2-(4-Hydroxyphenyl)-1,3-thiazolidine-4-carboxylic acid (7b). Yield: 99% (8.9 g), white 
solid, mp 165-167 ºC (lit. [16] 167-169 ºC). The 1H NMR spectrum showed the presence of the two 
diastereoisomers (2R,4R) and (2S,4R) (ratio 50:50); 1H NMR (400 MHz, (CD3)2SO): δ = 3.02-3.07 
and 3.13-3.17 (1H, 2 x m, ABX), 3.25-3.28 and 3.34-3.37 (1H, 2 x m, ABX), 3.82-3.86 and 4.24-4.26 
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(1H, 2 x m, ABX), 5.40 and 5.54 (1H, 2 x s, CHAr), 6.70 and 6.74 (2H, 2 x d, J = 8.4 Hz, ArH), 7.25 
and 7.31 (2H, 2 x d, J = 8.1 Hz, ArH). 
 
4.1.3. 5,5-Dimethyl-2-phenyl-1,3-thiazolidine-4-carboxylic acid (10). A solution of benzaldehyde 
(0.54 g, 5.1 mmol) in methanol (7 mL) was slowly added to a solution of D-penicillamine (0.69 g, 
4.6 mmol) in methanol (90 mL). After stirring overnight at room temperature the mixture was 
concentrated under reduced pressure and the residue was washed with diethyl ether to give a white 
solid (1.02 g, 93%). mp 160-162 ºC. The 1H NMR spectrum showed the presence of the two 
diastereoisomers (2R,4S) and (2S,4S) (ratio 38:62); Minor isomer: 1H NMR (400 MHz, CD3OD): δ = 
1.49 (3H, s), 1.71 (3H, s), 3.95 (1H, s), 5.92 (1H, CHPh), 7.54-7.55 (5H, m, ArH); Major isomer: 1H 
NMR (400 MHz, CD3OD): δ = 1.46 (3H, s), 1.74 (3H, s), 3.82 (1H, s), 5.68 (1H, CHPh), 7.37-7.41 
(5H, m). 
 
4.1.4. General procedure for the synthesis of 1H,3H-pyrrolo[1,2-c]thiazole carboxylates 8 and 11 
A solution of the appropriate thiazolidine-4-carboxylic acid (12.0 mmol), dimethyl acetylene 
dicarboxylate (1.5 equiv., 18.0 mmol) and Ac2O (40 mL) was heated at 110 ºC during the 4 h. The 
reaction was cooled to room temperature and was diluted with CH2Cl2 (100 mL). The organic phase 
was washed with saturated aqueous solution of NaHCO3 and with water, dried (Na2SO4) and 
evaporated off. The crude product was purified by flash chromatography [hexane-ethyl acetate]. 
 
4.1.4.1. Dimethyl (3R)-3-(4-methoxyphenyl)-5-methyl-1H,3H-pyrrolo[1,2-c]thiazole-6,7-
dicarboxylate (8a). Purification by flash chromatography [hexane-ethyl acetate (2:1)] gave 8a as a 
white solid (2.3 g, 52%); mp 80-82 ºC (from diethyl ether); IR (KBr): νmax = 1736, 1697, 1516, 1444, 
1288, 1209, 1088 cm-1; 1H NMR (400 MHz, CDCl3): δ = 2.00 (3H, s), 3.80 (3H, s), 3.83 (6H, s), 
4.30 (1H, d, J = 14.9 Hz ), 4.47 (1H, d, J = 14.9 Hz), 6.27 (1H, s), 6.86 (2H, d, J = 8.6 Hz), 7.02 (2H, 
d, J = 8.6 Hz); 13C NMR (100 MHz, CDCl3): δ = 11.42, 29.98, 51.38, 51.56, 55.36, 64.87, 106.71, 
114.59, 117.38, 127.23, 130.73, 131.93, 140.43, 160.08, 164.08, 165.36; HRMS (EI-TOF) m/z 
361.0988 (M+, C18H19NO5S requires 361.0984). 
 
4.1.4.2. Dimethyl (3R)-3-(4-acethoxyphenyl)-5-methyl-1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylate (8b). 
Purification by flash chromatography [hexane-ethyl acetate (3:1), hexane-ethyl acetate (2:1), then hexane-
ethyl acetate (1:1)] gave 8b as a white solid (2.0 g, 42%); mp 90-92 ºC (from ethyl acetate/hexane); IR (KBr): 
νmax = 1766, 1734, 1709, 1437, 1367, 1296, 1215, 1095 cm-1; 1H NMR (400 MHz, CDCl3): δ = 2.03 (3H, s), 
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2.26 (3H, s), 3.81 (6H, m), 4.29 (1H, d, J = 14.9 Hz), 4.44 (1H, d, J = 14.9 Hz), 6.32 (1H, s), 7.07 (4H, s, 
ArH); 13C NMR (100 MHz, CDCl3): δ = 11.37, 20.97, 29.88, 51.29, 51.45, 64.23, 106.83, 117.36, 122.34, 
126.84, 130.62, 137.59, 140.34, 150.90, 163.84, 165.10, 168.94; HRMS (EI-TOF) m/z 389.0935 (M+, 
C19H19NO6S requires 389.0933). 
 
4.1.4.3. Dimethyl (3S)-1,1,5-trimethyl-3-phenyl-1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylate 
(11). Purification by flash chromatography [hexane-ethyl acetate (3:1), then hexane-ethyl acetate 
(2:1)] gave 7 as an yellowish oil (3.1 g, 73%); IR (KBr): νmax = 1709, 1531, 1441, 1396, 1294, 1213, 
1172 cm-1; 1H NMR (400 MHz, CDCl3): δ = 1.84 (3H, s), 1.90 (3H, s), 1.95 (3H, s), 3.80 (3H, s), 
3.84 (3H, s), 6.34 (1H, s, CHPh), 7.07-7.09 (2H, m, ArH), 7.31-7.36 (3H, m, ArH); 13C NMR (100 
MHz, CDCl3): δ = 11.26, 30.78, 31.92, 51.55, 51.58, 52.86, 64.17, 106.28, 117.67, 125.80, 128.79, 
129.20, 129.21, 140.38, 145.73, 164.98, 165.50; HRMS (EI-TOF) m/z 359.1195 (M+, C19H21NO4S 
requires 359.1191). 
 
4.1.5. General procedure for the synthesis of 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazole 
carboxylates 9 and 12 
A solution of the appropriate 5-methyl-1H,3H-pyrrolo[1,2-c]thiazole-carboxylate 8 or 11 (2.9 
mmol) in dry dichloromethane (30 mL) was added dropwise to a suspension of lithium aluminium 
hydride (2.2 eq., 0.24 g, 6.4 mmol) in anhydrous diethyl ether (40 mL) at 0 ºC. The solution was 
refluxed for 1.5 h after the addition was completed and then cooled on an ice bath. The excess of 
hydride was carefully decomposed by addition of ethyl acetate followed by slow addition of water 
(0.3 mL), NaOH 15% (0.3 mL) and water (0.9 mL). The mixture was filtered through celite and the 
inorganic residue was washed with several portions of hot dichloromethane. The filtrate was dried 
(Na2SO4) and the solvent evaporated off. The crude product was purified by flash chromatography 
[hexane-ethyl acetate] or recrystallization. 
For the synthesis of compound 8b 3.3 equivalents of lithium aluminium hydride (0.36 g, 9.6 
mmol) were used. In this case the excess of hydride was eliminated by the addition of ethyl acetate 
followed by slow addition of water (0.4 mL), NaOH 15% (0.4 mL) and water (1.2 mL). 
 
4.1.5.1. (3R)-6,7-Bis(hydroxymethyl)-3-(4-methoxyphenyl)-5-methyl-1H,3H-pyrrolo[1,2-c]thiazole (9a). 
Recrystallization with diethyl ether gave 9a as a white solid (0.52 g, 58%); mp 119-121 ºC; IR (KBr): νmax = 
3392, 1614, 1514, 1435, 1338, 1286, 1255, 1172, 1009 cm-1; 1H NMR (400 MHz, CDCl3): δ = 1.84 (3H, s), 
2.38 (1H, bs), 2.53 (1H, bs), 3.79 (3H, s), 4.08 (1H, d, J = 12.8 Hz), 4.28 (1H, d, J = 12.8 Hz), 4.48 (1H, d, J = 
12.0 Hz), 4.53 (1H, d, J = 12.0 Hz), 4.59 (2H, s), 6.21 (1H, s, CHAr), 6.84 (2H, d, J = 8.4 Hz, ArH), 7.02 (2H, 
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d, J = 8.4 Hz, ArH); 13C NMR (100 MHz, CDCl3): δ = 9.96, 27.62, 55.33, 56.48, 56.79, 64.26, 113.30, 
114.34, 123.09, 123.46, 127.25, 131.49, 133.38, 159.73; HRMS (EI-TOF) m/z 305.1085 (M+, C16H19NO3S 
requires 305.1086); [α]D20 = + 230 (c 1, CH2Cl2). 
 
4.1.5.2. (3R)-6,7-Bis(hydroxymethyl)-3-(4-hydroxyphenyl)-5-methyl-1H,3H-pyrrolo[1,2-c]thiazole (9b). 
Recrystallization with diethyl ether gave 9b as a pale brown solid (0.43 g, 52%); mp > 220 ºC (with 
decomposition); IR (KBr): νmax = 3263, 1612, 1518, 1427, 1363, 1277, 1240, 982 cm-1; 1H NMR (400 MHz, 
CD3OD): δ = 1.84 (3H, s), 4.07 (1H, d, J = 13.1 Hz), 4.29 (1H, d, J = 13.1 Hz), 4.43 (2H, s), 4.52 (1H, d, J = 
12.1 Hz), 4.56 (1H, d, J = 12.1 Hz), 6.30 (1H, s, CHAr), 6.71 (2H, d, J = 8.4 Hz, ArH), 6.92 (2H, d, J = 8.4 
Hz, ArH); 13C NMR (100 MHz, CD3OD): δ = 9.94, 28.12, 56.16, 56.62, 65.24, 114.13, 116.45, 124.06, 
124.32, 128.47, 132.93, 134.34, 158.72; HRMS (ESI-TOF) m/z 314.0829 ([M+Na]+, C15H17NO3SNa requires 
314.0821); [α]D20 = + 245 (c 1, MeOH). 
 
4.1.5.3. (3S)-6,7-Bis(hydroxymethyl)-1,1,5-trimethyl-3-phenyl-1H,3H-pyrrolo[1,2-c]thiazole (12). 
Purification by flash chromatography [hexane-ethyl acetate (1:2), then hexane-ethyl acetate (1:4)] 
gave 12as a colourless oil (0.45 g, 51%); IR (film): νmax = 3375, 1537, 1456, 1433, 1402, 1363, 
1120, 989 cm-1; 1H NMR (400 MHz, CDCl3): δ = 1.78 (3H, s), 1.83 (3H, s), 1.85 (3H, s), 4.49 (1H, 
d, J = 12.1 Hz, CH2), 4.53 (1H, d, J = 12.1 Hz, CH2), 4.65 (2H, s, CH2), 6.30 (1H, s, CHPh), 7.06-
7.09 (2H, m, ArH), 7.29-7.32 (3H, m, ArH); 13C NMR (100 MHz, CDCl3): δ = 9.87, 32.64, 33.82, 
52.00, 55.28, 56.27, 64.04, 111.90, 121.86, 123.90, 125.91, 128.36, 128.96, 140.00, 141.82; HRMS 
(EI-TOF) m/z 303.1295 (M+, C17H21NO2S requires 303.1293). 
[α]D20 = - 205 (c 1, CH2Cl2). 
 
4.2 Biological evaluation 
 
4.2.1 Cell culture 
Human breast carcinoma cell lines HCC1954 and HCC1806 were cultured in RPMI-1640 medium 
(Sigma Aldrich®, EUA) supplemented with 10% and 5% of fetal bovine serum (FBS) (Sigma 
Aldrich®, EUA), respectively, 2.5 g.L-1 of D-(+)-glucose (Sigma Aldrich®, EUA), 400 mM of 
sodium pyruvate (Gibco®, UK), 100 U.mL-1 of penicillin and 100 U.mL-1 of streptomycin (Gibco®, 
UK), under an atmosphere containing 5% CO2 at 37 ºC. Human breast adenocarcinoma cell line 
MCF7 was cultured in DMEM (Sigma Aldrich®, EUA) supplemented with 10% of FBS, 100 mM of 
sodium pyruvate, 100 U.mL-1 of penicillin and 100 U.mL-1 of streptomycin, under an atmosphere 
containing 5% CO2 at 37 ºC. 
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4.2.2 Cytotoxicity 
The cells were plated in 96-well culture plates at a density of 2x104 cells per well and incubated 
overnight to allow cell attachment. All compounds were dissolved in dimethylsulphoxide (DMSO, 
Sigma Aldrich®, EUA) at various concentrations and diluted in culture media. Cells were then 
incubated with the compounds for 24, 48, 72 and 96 h. The metabolic activity was determined by 
MTT assay [17,18] (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; MTT, Sigma 
Aldrich®, EUA). Briefly, cell culture were washed with phosphate saline buffer (PBS: 137 mM 
NaCL, 2.7 mM KCl, 10 mM Na2HPO4.2H2O, 2.0 mM KH2PO4; pH = 7.4) and incubated with 0.5 
mg.mL-1 MTT (Sigma Aldrich®, EUA), pH = 7.4, at 37 ºC for 4 h. Then, formazan crystals were 
dissolved in acid isopropanol (0.04 M 37% hydrochloric acid in isopropanol; Sigma Aldrich®, 
EUA). The results allowed to establish dose-response curves and to calculate IC50 values, the 
concentration required to inhibit cell proliferation by 50%. 
 
4.2.3 Clonogenic assay 
For the clonogenic assay cells were plated in 6-well culture plates at a density of 5x105 cells per 
well and incubated to allow cell attachment. Incubation with the IC50 of 3 or 9b was made for 48 h. 
Cells were harvested, counted and 1000, 3000 or 5000 cells were plated. After 12 days, cells were 
fixed with methanol, stained with crystal violet and individual colonies were counted. 
 
4.2.4 Sulphorhodamine B assay 
For total protein production evaluation, cells were plated in 24-well culture plates at a density of 
4x104 cells per well and incubated overnight to allow cell attachment. Cell cultures were incubated 
with IC50 concentrations of the compounds 3 and 9b for 48 h (final DMSO concentration 1%). SRB 
assay was performed as described [19]. Briefly, cells were washed with ultra-pure water and twice 
with PBS. Cells were then incubated with 1% acetic acid in methanol for 30 minutes prior to 
incubation with 0.4% SRB (Sigma Aldrich®, EUA) dissolved in 1% acetic acid (Sigma Aldrich®, 
EUA) in methanol (Sigma Aldrich®, EUA) for 1 h in the dark. After incubation SRB crystals were 
dissolved in 10 mM Tris-NaOH, pH 10. 
 
4.2.5 Cell viability and types of cell death 
For analysis of cell viability and types of cell death, 2x106 cells were incubated overnight to allow 
attachment and then were treated with IC50 of 3 or 9b for 48 h (final DMSO concentration 0.1 %). 
Then, cells were collected, centrifuged and washed with PBS prior to incubation with binding buffer, 
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2.5 µL An-V–FITC and 1 µL propidium iodide (kit Immunotech) for 15 minutes, at 4 ºC in the dark. 
400 µL PBS were added and samples were analysed in a FACSCalibur cytometer (BD Biosciences, 
EUA). Excitation was set at 488 nm, and the emission filters were set at for An-V–FITC and 
propidium iodide, respectively. 
 
4.2.6 P53 expression 
Western Blot was used to evaluate the expression of p53 protein. Cells were treated with the IC50 
of 3 or 9b during 48 h. Total protein extracts were prepared on ice using a solution of radioimmuno 
precipitation assay (RIPA) buffer supplemented with cOmplete Mini (Roche). After sonication and 
centrifugation at 14000 g, the samples were kept at -80 ºC prior use. Protein content was determined 
by bicinchoninic (BCA) method. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) was held using a 10% acrylmide gel for 20 min at 80 V followed by 160 V till 1h 10min. 
Subsequently proteins were electrotransfered to nitrocellulose (PVDF) membranes at 100 V during 1 
hour. Blocking of PVDF membranes was performed with 4% bovine serum albumin (BSA) in tris-
buffered saline tween-20 (TBS-T) for 1 hour at room temperature with stirring. Incubation with 
primary antibodies, Actin (Sigma-Aldrich) and p53 (mouse anti-human p53-DO7, Santa Cruz 
Biotechnology, Inc.) was performed overnight at 4ºC. After several washes with TBS-T, membranes 
were incubated with secondary antibody (anti-mouse antibody) for 1 hour at room temperature. New 
washes were performed and ultimately the blots were stained with fluorescent reagent elemental 
chlorine free (ECF) and reading was performed in 9000 Typhoon FLA equipment. Quantification of 
fluorescence was performed using the ImageQuant Software (GE Healthare). 
 
4.2.7 Bax/Bcl-2 analysis 
Bax and Bcl-2 expression was also analysed by flow cytometry using monoclonal antibodies 
conjugated with phycoerythrin (PE) and FITC respectively. Briefly, 2x106 cells were incubated 
overnight to allow cell attachment and were treated with IC50 of 3 or 9b for 48 h (DMSO 0.1%). 
Cells were collected, centrifuged and washed with PBS prior to incubation with permeabilizing 
solution (Intracell Kit, Immunostep), 3 µL Bax-PE (Santa Cruz Biotechnology, Inc.) and 3 µL Bcl-2-
FITC (Santa Cruz Biotechnology, Inc.), for 15 minutes in the dark. After washing with PBS, analysis 
was performed in the FACSCalibur cytometer with excitation at 488 nm, and emission filter at 
530/30 and 585/42 for BCl-2 and Bax, respectively. 
 
4.2.8 Cell cycle analysis 
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For analysis of DNA content, 2x106 cells were incubated overnight to allow cell attachment and 
then were treated with IC50 of 3 or 9b for 48 h (DMSO 0.1 %). Cells were collected, centrifuged, and 
fixed with ice-cold ethanol (70 %) for 30 minutes in the dark. Then, cells were washed with PBS and 
incubated with PI/RNase solution (Immunostep) for 15 minutes RT. Cells were analysed in the 
FACSCalibur cytometer with an excitation wavelenght of 488 nm, and emission filter at of 585/42. 
 
4.2.9 Comet assay 
Damage in cell DNA were analysed with alkaline single-cell gel electrophoresis, comet assay [20]. 
Briefly, 5x105 cells were treated with IC50 of 3 or 9b and with the triple of the first value (DMSO 
0.1% for both cases) for 48 h. Positive control was prepared from negative control with 
administration of 20 nM of hydroxide peroxide (Sigma Aldrich®, EUA) for 15 minutes at -4ºC. 
Controls and treated cells were than collected and counted in order to prepare a suspension with 
5x104 g.mL-1. Cells suspensions were diluted 1:1 in 1% low melting point agarose and applied in 
Starfrost slides previously overlaid with 1% normal melting point agarose. The sides were 
submerged in alkaline lysis solution (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, 10% DMSO and 1% 
Triton x-100, Sigma Aldrich®, EUA) overnight. Slides were equilibrated in alkaline electrophoresis 
buffer (300 mM NaOH and 1 mM EDTA, pH>13) and then were submitted to a potential difference 
of 25 V and current of 1 A, for 15 minutes. After electrophoresis, slides were incubated in 
neutralizing buffer (0.4 M Tris, pH 7.4) 3 times, 5 minutes each, and stained with 25 µg.mL-1 
ethidium bromide for 20 minutes. Slides were washed in distilled water and visualized in a 
fluorescent inverted microscope Motic with excitation at 546 nm with a 100 W mercury lamp with 
emission at 580/10. Image acquisition was performed in Motic Images 2.0 (Microscope world, 
EUA). 
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IC50 and confidence intervals for compounds 3, 6, 9a, 9b and 12 against HCC1806, HCCC1954 
and MCF7 cell lines given in Table 1. 1H NMR spectra for all new compounds and 13C NMR spectra for 
compounds 9 and 12. Supplementary data associated with this article can be found in the online 
version at doi:xxxxxxx  
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Captions: 
 
Scheme 1. Synthesis of 1H,3H-pyrrolo[1,2-c]thiazoles 9. Reagents and conditions: (i) Ac2O, 
DMAD, reflux, 4 h, 8a: 52%, 8b: 42%;(ii) DCM, LiAlH4 in diethyl ether, 0 ºC; (iii) reflux, 1.5 h, 9a: 
58%, 9b: 52%. 
 
Scheme 2. Synthesis of 1H,3H-pyrrolo[1,2-c]thiazole 12. Reagents and conditions: (i) Ac2O, 
DMAD, reflux, 4 h, 11: 73%; (ii) DCM, LiAlH4 in diethyl ether, 0 ºC; (iii) reflux, 1.5 h, 12: 51%. 
 
Figure 1. Cytotoxicity against MCF7 breast cancer human cell line (72 h incubation time) [4,5]. 
 
Figure 2. Survival factor of MCF7 and HCC1806 cell lines incubated with 3 and 9b during 48 h. Results are presented as 
mean ± SD (n≥8). The * represent significant differences between the respective control population. Statistical 
significance: ***p<0.001. 
 
Figure 3. Protein content of MCF7 and HCC1806 cell lines incubated with 3 and 9b during 48 h. Results are presented 
as mean ± SD (n≥8). The * represent significant differences between the respective control population. Statistical 
significance: ***p<0.001. 
 
Figure 4. Cell viability of MCF7 and HCC1806 cell lines incubated with 3 and 9b during 48 h. Cell viability results 
represent the percentage of viable cells, cells in apoptosis, cells in late apoptosis /necrosis and cells in necrosis and are 
presented as mean ± SD (n≥5). The * represent significant differences between the respective control population. 
Statistical significance: *p<0.05; **p<0.01; ***p<0.001. 
 
Figure 5.  p53 Protein expression. The graphic represents ratio of p53 expression versus β-actin and the image refers to a 
representative immunoblot of p53 and β-actin. Results are presented as mean ± SD (n≥3). The * represent significant 
differences between the respective control population. Statistical significance: **p<0.01.  
 
Figure 6. Ratio of the mean fluorescence intensity of Bax and the mean fluorescence intensity of Bcl2 in MCF7 and 
HCC1806 cell lines incubated with 3 and 9b during 48 h. Results are presented as mean ± SD (n≥5). The * represent 
significant differences between the respective control population. Statistical significance: **p<0.01; ***p<0.001. 
 
Figure 7. Cell cycle analysis of MCF7 and HCC1806 cell lines incubated with 3 and 9b during 48 h. Cell cycle results 
show the percentage of cell populations in the sub-Go, G0/G1, S and G2/M phases. Results are presented as mean ± SD 
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(n≥5). The * represent significant differences between the respective control population. Statistical significance: *p<0.05; 
**p<0.01; ***p<0.001. 
 
Figure 8. Representative images of the Comet Assay in the MCF7 and HCC1806 cell lines after 48 h of incubation with 
3 and 9b in the concentrations equal to the IC50 and three times this value. A: Control, untreated cell cultures, 100x; B: 
positive control, 100x; C: positive control, 400x; D: 3 IC50 treated cultures, 100x; E: 3 3x IC50 treated cultures, 100x; F: 
9b IC50 treated cultures, 100x; G: 9b 3x IC50 treated cultures, 100x. 
 
Table 1. IC50 values of the compounds 3, 6, 9 and 12 for 24, 48, 72 and 96 h of incubation in the MCF7, HCC1954 and 
HCC1806 cell lines.a 
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Figure 1. Cytotoxicity against MCF7 breast cancer human cell line (72 h incubation time) [4,5]. 
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Scheme 1. Synthesis of 1H,3H-pyrrolo[1,2-c]thiazoles 9. Reagents and conditions: (i) Ac2O, 
DMAD, reflux, 4 h, 8a: 52%, 8b: 42%;(ii) DCM, LiAlH4 in diethyl ether, 0 ºC; (iii) reflux, 1.5 h, 9a: 
58%, 9b: 52%. 
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Scheme 2. Synthesis of 1H,3H-pyrrolo[1,2-c]thiazole 12. Reagents and conditions: (i) Ac2O, 
DMAD, reflux, 4 h, 11: 73%; (ii) DCM, LiAlH4 in diethyl ether, 0 ºC; (iii) reflux, 1.5 h, 12: 51%. 
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Table 1. IC50 values of the compounds 3, 6, 9 and 12 for 24, 48, 72 and 96 h of incubation in the MCF7, HCC1954 and 
HCC1806 cell lines.a 
Compd Incubation 
time 
IC50 (µM)b 
HCC1806 HCC1954 MCF7 
3 24 h >100 98.2 12.25 
48 h 81.4 27.0 1.95 
72 h 51.3 26.2 1.05 
96 h 13.9 24.9 0.65 
6 
 
24 h >100 >100 1.755 
48 h 63.1 56.8 0.545 
72 h 78.5 14.8 0.545 
96 h 28.7 11.8 0.305 
9a 24 h 89.0 >100 >100 
48 h 28.0 84.4 46.9 
72 h 19.4 56.1 32.7 
96 h 12.3 19.2 6.6 
9b 24 h 80.3 >100 >100 
48 h 26.4 65.6 86.2 
72 h 11.9 46.6 53.9 
96 h 5.4 27.4 29.5 
12 24 h >100 99.5 >100 
48 h 41.7 69.0 >100 
72 h 26.9 55.9 >100 
96 h 21.3 33.5 >100 
aCells were incubated with DMSO solutions of the selected compounds, washed and then cell proliferation was evaluated by MTT test; 
bConcentration needed to inhibit cell proliferation by 50% as determined from dose-response curves by exponential decay fitting 
(r2>0.9). 
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Figure 2. Survival factor of MCF7 and HCC1806 cell lines incubated with 3 and 9b during 48 h. Results are presented as 
mean ± SD (n≥8). The * represent significant differences between the respective control population. Statistical 
significance: ***p<0.001. 
 
 
 
Figure 3. Protein content of MCF7 and HCC1806 cell lines incubated with 3 and 9b during 48 h. Results are presented 
as mean ± SD (n≥8). The * represent significant differences between the respective control population. Statistical 
significance: ***p<0.001. 
 
 
Figure 4. Cell viability of MCF7 and HCC1806 cell lines incubated with 3 and 9b during 48 h. Cell viability results 
represent the percentage of viable cells, cells in apoptosis, cells in late apoptosis /necrosis and cells in necrosis and are 
presented as mean ± SD (n≥5). The * represent significant differences between the respective control population. 
Statistical significance: *p<0.05; **p<0.01; ***p<0.001. 
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Figure 5.  p53 Protein expression. The graphic represents ratio of p53 expression versus β-actin and the image refers to a 
representative immunoblot of p53 and β-actin. Results are presented as mean ± SD (n≥3). The * represent significant 
differences between the respective control population. Statistical significance: **p<0.01.  
 
 
Figure 6. Ratio of the mean fluorescence intensity of Bax and the mean fluorescence intensity of Bcl2 in MCF7 and 
HCC1806 cell lines incubated with 3 and 9b during 48 h. Results are presented as mean ± SD (n≥5). The * represent 
significant differences between the respective control population. Statistical significance: **p<0.01; ***p<0.001. 
 
 
Figure 7. Cell cycle analysis of MCF7 and HCC1806 cell lines incubated with 3 and 9b during 48 h. Cell cycle results 
show the percentage of cell populations in the sub-Go, G0/G1, S and G2/M phases. Results are presented as mean ± SD 
(n≥5). The * represent significant differences between the respective control population. Statistical significance: *p<0.05; 
**p<0.01; ***p<0.001. 
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Figure 8. Representative images of the Comet Assay in the MCF7 and HCC1806 cell lines after 48 h of incubation with 
3 and 9b in the concentrations equal to the IC50 and three times this value. A: Control, untreated cell cultures, 100x; B: 
positive control, 100x; C: positive control, 400x; D: PT1 IC50 treated cultures, 100x; E: 3 3x IC50 treated cultures, 100x; 
F: 9b IC50 treated cultures, 100x; G: 9b 3x IC50 treated cultures, 100x. 
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IC50 and confidence intervals for compounds 3, 6, 9 and 12 
against HCC1806, HCCC1954 and MCF7 cell lines 
 
Table S1. IC50 of the compounds 3, 6, 9 and 12 for 24, 48, 72 and 96h of incubation in the HCC1806, 
HCC1954 and MCF7 cell lines. The IC50 and respective confidence intervals at 95% are expressed in µM.a  
 
Compd 
 
Incubation 
time 
HCC1806 HCC1954 MCF7 
IC50 (µM)b CI95%c IC50 (µM)b CI95%c IC50 (µM)b CI95%c 
3 24 h >100 - 98.2 [90.9; 106.1] 12.2[5] - 
48 h 81.4 [63.7; 89.0] 27.0 [1.4; 30.5] 1.9[5] - 
72 h 51.3 [37.1; 57.7] 26.2 [19.0; 29.4] 1.0[5] - 
96 h 13.9 [10.2; 15.6] 24.9 [16.0; 29.2] 0.6[5] - 
6 24 h >100 - >100 - 1.75[5] - 
48 h 63.1 [45.9; 70.8] 56.8 [40.3; 64.3] 0.54[5] - 
72 h 78.5 [67.7; 82.8] 14.8 [11.7; 16.2] 0.54[5] - 
96 h 28.7 [21.9; 31.7] 11.8 [10.1; 12.5] 0.30[5] - 
9a 24 h 89.0 [72.9; 108.7] >100 - >100 - 
48 h 28.0 [23.3; 32.3] 84.4 [75.3; 90.1] 46.9 [39.9; 53.2] 
72 h 19.4 [12.8; 26.9] 56.1 [38.5; 69.5] 32.7 [28.0; 36.9] 
96 h 12.3 [6.7; 19.9] 19.2 - 6.6 [3.0; 12.4] 
9b 24 h 80.3 [69.6; 92.8] >100 - >100 - 
48 h 26.4 [19.7; 33.3] 65.6 [48.0; 78.4] 86.2 [8.7; 89.1] 
72 h 11.9 [9.0; 14.7] 46.6 [42.3; 49.3] 53.9 [42.1; 65.5] 
96 h 5.4 [3.2; 8.2] 27.4 [25.1; 28.8] 29.5 [18.3; 42.7] 
12 24 h >100 [32.6; 50.6]- 99.5 [90.7; 109.2] >100 - 
48 h 41.7 [21.9; 31.6] 69.0 [54.4; 79.0] >100 - 
72 h 26.9 [15.1; 27.9] 55.9 [49.6; 59.9] >100 - 
96 h 21.3  33.5 [30.5; 35.3] >100 - 
 
a
 Cells were incubated during 96 h with a DMSO solution of the selected compounds, washed and then cell proliferation was evaluated 
by MTT test; b Concentration needed to inhibit cell proliferation by 50% as determined from dose-response curves by exponential 
decay fitting (r2>0.9); c Confidence interval at 95%. 
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1H and 13C NMR spectra 
 
 
 
Figure S1. 1H NMR spectrum of compound 10 (400 MHz, CD3OD). 
 
 
 
 
Figure S2. 1H NMR spectrum of compound 8a (400 MHz, CDCl3). 
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Figure S3. 1H NMR spectrum of compound 8b (400 MHz, CDCl3). 
 
 
 
 
Figure S4. 1H NMR spectrum of compound 11 (400 MHz, CDCl3). 
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Figure S5. 1H NMR spectrum of compound 9a (400 MHz, CDCl3). 
 
 
 
Figure S6. 13C NMR spectrum of compound 9a (100 MHz, CDCl3). 
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Figure S7. 1H NMR spectrum of compound 9b (400 MHz, CD3OD). 
 
 
 
Figure S8. 13C NMR spectrum of compound 9b (100 MHz, CD3OD). 
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Figure S9. 1H NMR spectrum of compound 12 (400 MHz, CDCl3). 
 
 
 
Figure S10. 13C NMR spectrum of compound 12 (100 MHz, CDCl3). 
